Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;34(1):53-62.
doi: 10.3803/EnM.2019.34.1.53.

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement

Sang Ouk Chin  1 , Cheol Ryong Ku  2 , Byung Joon Kim  3 , Sung Woon Kim  1 , Kyeong Hye Park  4 , Kee Ho Song  5 , Seungjoon Oh  1 , Hyun Koo Yoon  6 , Eun Jig Lee  2 , Jung Min Lee  7 , Jung Soo Lim  8 , Jung Hee Kim  9 , Kwang Joon Kim  10 , Heung Yong Jin  11 , Dae Jung Kim  12 , Kyung Ae Lee  11 , Seong Su Moon  13 , Dong Jun Lim  7 , Dong Yeob Shin  2 , Se Hwa Kim  14 , Min Jeong Kwon  15 , Ha Young Kim  16 , Jin Hwa Kim  17 , Dong Sun Kim  18 , Chong Hwa Kim  19
Affiliations
Review

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement

Sang Ouk Chin et al. Endocrinol Metab (Seoul). 2019 Mar.

Abstract

The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

Keywords: Acromegaly; Lanreotide; Octreotide; Pasireotide; Somatostatin analogues.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Initial dose and up-/down-titration of octreotide long-acting release (LAR) and lanreotide autogel (ATG) in patients with acromegaly. SSA, somatostatin analogues; OCT, octreotide; LAN, lanreotide; GH, growth hormone.
Fig. 2
Fig. 2. Switching between octreotide long-acting release (LAR) and lanreotide autogel (ATG) during the medical treatment of acromegaly.
See this image and copyright information in PMC

References

    1. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189–3202. - PMC - PubMed
    1. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 2010;72:203–208. - PMC - PubMed
    1. Kwon O, Song YD, Kim SY, Lee EJ Rare Disease Study Group; Science and Research Committee; Korean Endocrine Society. Nationwide survey of acromegaly in South Korea. Clin Endocrinol (Oxf) 2013;78:577–585. - PubMed
    1. Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951. - PubMed
    1. Wass JA, Turner HE, Adams CB. The importance of locating a good pituitary surgeon. Pituitary. 1999;2:51–54. - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources